CoChat
Sign Up
Cited by 158

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

Urfer, Silvan R., Kaeberlein, Tammi L., Mailheau, Susan, Bergman, Philip J., Creevy, Kate E., Promislow, Daniel E. L., Kaeberlein, Matt·2017·GeroScience
DOI 10.1007/s11357-017-9972-z
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11357-017-9972-z

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A small pilot study found that treatment with 0.05 mg/kg or 0.1 mg/kg rapamycin three times per week did not cause statistically significant side effects but did improve measurements of cardiac function (fractional shortening and diastolic function) in dogs.

    “A small pilot study found that treatment with 0.05 mg/kg or 0.1 mg/kg rapamycin three times per week did not cause statistically significant side effects but did improve measurements of cardiac function (fractional shortening and diastolic function) 48.”

    From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [48]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Alexandre J, Raymond E, Armand JP (1999) Rapamycin and CCI-779. Bull Cancer 86(10):808–811
  2. Anisimov VN et al (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230–4236 · DOI
  3. Bitto A et al (2016) Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. elife 5:e16351 · DOI · Paper page
  4. Boers-Doets CB et al (2013) Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 9(12):1883–1892 · DOI
  5. Brattstrom C et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65(9):1272–1274 · DOI
  6. Chen C, Liu Y, Zheng P (2009) mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2(98):ra75 · DOI · Paper page
  7. Dai DF et al (2014) Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13(3):529–539 · DOI
  8. Detweiler DK, Patterson DF (1965) The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 127(1):481–516 · DOI
  9. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63(23):8451–8460
  10. Fischer KE et al (2015) Health effects of long-term rapamycin treatment: the impact on mouse health of enteric rapamycin treatment from four months of age throughout life. PLoS One 10(5):e0126644 · DOI
  11. Flynn JM et al (2013) Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12(5):851–862 · DOI
  12. Gamaldo AA, Ferrucci L, Rifkind J, Longo DL, Zonderman AB (2013) Relationship between mean corpuscular volume and cognitive performance in older adults. J Am Geriatr Soc 61(1):84–89 · DOI
  13. Gilmore KM, Greer KA (2015) Why is the dog an ideal model for aging research? Exp Gerontol 71:14–20 · DOI
  14. Halloran J et al (2012) Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223:102–113 · DOI
  15. Johnson SC, Martin GM, Rabinovitch PS, Kaeberlein M (2013) Preserving youth: does rapamycin deliver? Sci Transl Med 5(211):211fs240 · DOI
  16. Johnson SC, Sangesland M, Kaeberlein M, Rabinovitch PS (2015) Modulating mTOR in aging and health. Interdiscip Top Gerontol 40:107–127 · DOI
  17. Jones TC, Zook BC (1965) Aging changes in the vascular system of animals. Ann N Y Acad Sci 127(1):671–684 · DOI
  18. Kaeberlein M (2013) mTOR inhibition: from aging to autism and beyond. Scientifica (Cairo) 2013:849186
  19. Kaeberlein M (2014) Rapamycin and aging: when, for how long, and how much? J Genet Genomics 41(9):459–463 · DOI
  20. Kaeberlein M (2015) The biology of aging: citizen scientists and their pets as a bridge between research on model organisms and human subjects. Vet Pathol · DOI
  21. Kaeberlein M, Rabinovitch PS, Martin GM (2015) Healthy aging: the ultimate preventative medicine. Science 350(6265):1191–1193 · DOI · Paper page
  22. Kaeberlein M, Creevy KE, Promislow DE (2016) The dog aging project: translational geroscience in companion animals. Mammalian genome: official journal of the International Mammalian Genome Society 27(7–8):279–288 · DOI
  23. Kealy RD et al (2002) Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 220(9):1315–1320 · DOI
  24. Khan KH et al (2016) Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist 21(7):855–860 · DOI
  25. Lamming DW et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335(6076):1638–1643 · DOI · Paper page
  26. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293 · DOI · Paper page
  27. Larson JC et al (2016) Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res 77(1):65–71 · DOI
  28. Majumder S et al (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11(2):326–335 · DOI
  29. Miller RA et al (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66(2):191–201 · DOI · Paper page
  30. Neff MW, Rine J (2006) A fetching model organism. Cell 124(2):229–231 · DOI
  31. Paoloni MC et al (2010) Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5(6):e11013 · DOI
  32. Parikh JD, Hollingsworth KG, Wallace D, Blamire AM, MacGowan GA (2016) Normal age-related changes in left ventricular function: role of afterload and subendocardial dysfunction. Int J Cardiol 223:306–312 · DOI
  33. Pitt JN, Kaeberlein M (2015) Why is aging conserved and what can we do about it? PLoS Biol · DOI
  34. Ross C et al (2015) Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) 7(11):964–973 · DOI
  35. Sierra F, Kohanski R (2017) Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience 39(1):1–5 · DOI · Paper page
  36. Singh JP et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83(6):897–902 · DOI · Paper page
  37. Tardif S et al (2015) Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70(5):577–587 · DOI
  38. Team RC (2016) R: a language and environment for statistical computing. R foundation for statistical Computing, Vienna
  39. Templeton GH, Willerson JT, Platt MR, Weisfeldt M (1976) Contraction duration and diastolic stiffness in aged canine left ventricle. Recent Adv Stud Cardiac Struct Metab 11:169–173
  40. Urfer SR et al (2017) Asymptomatic heart valve dysfunction in healthy middle-aged companion dogs and its implications for cardiac aging. Geroscience 39(1):43–50 · DOI
  41. Weinreich J et al (2011) Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling. Eur Surg Res 47(1):39–44 · DOI
  42. Wilkinson JE et al (2012) Rapamycin slows aging in mice. Aging Cell 11(4):675–682 · DOI · Paper page
  43. Xu B & Daimon M (2016) Cardiac aging phenomenon and its clinical features by echocardiography. J Echocardiogr · DOI
  44. Yi H et al (2014) Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med 92(6):641–650 · DOI

Cited by

Sorted by citations

Metadata

Authors
Urfer, S. R., Kaeberlein, T. L., Mailheau, S., Bergman, P. J., Creevy, K. E., Promislow, D. E. L., & Kaeberlein, M.
ORCID
Kaeberlein, Matt
Venue
GeroScience
Publisher
Springer Science and Business Media LLC
Published
2017-04
Volume
39
Issue
2
Pages
117-127
ISSN
  • 2509-2715
  • 2509-2723
DOI
10.1007/s11357-017-9972-z
Cited by
158
References
7
Language
en
Licence
Funders
  • National Institute on Aging (P30AG013280)
  • The Donner Foundation (DonnerUW1)
  • Irish Wolfhound Association of New England (IWANEUW1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review